Mallinckrodt PLC (MNK) reported quarterly earnings results on Tuesday, Aug-2-2016. The company said it had a profit of $2.20 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.19. Analysts had a consensus of $2.01. The company posted revenue of $970.60 million in the period, compared to analysts expectations of $921.82 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.
Many Wall Street Analysts have commented on Mallinckrodt PLC. Company shares were Reiterated by Mizuho on Jul 21, 2016 to “Buy”, Firm has raised the Price Target to $ 83 from a previous price target of $80 .Goldman Initiated Mallinckrodt PLC on Jun 6, 2016 to “Neutral”, Price Target of the shares are set at $73.
Mallinckrodt PLC (MNK) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $67.12 and reached the intraday high at $68.47. The bulls started the profit booking and pushed the shares to intraday low of $66.76. The trading session was marked by a volume range of 13,75,132 shares exchanging hands. The 52-week high of the shares is $125.35 and the 52-week low is $50.9. The market cap of the company stands at $7,362 M and there are 10,93,25,511 shares in public circulation.
In a different news, on May 11, 2016, Matthew K Harbaugh (CFO) purchased 500 shares at $59.37 per share price. According to the SEC, on May 10, 2016, Hugh M. O’neill (Sr. VP & Pres, ARD) purchased 1,653 shares at $60.99 per share price. On May 9, 2016, Steven J. Romano (Sr. VP & Chief Scientific Ofcr) purchased 900 shares at $56.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Mallinckrodt public limited company (Mallinckrodt) is a global specialty pharmaceuticals company. The Company develops manufactures markets and distributes both branded and generic specialty pharmaceuticals active pharmaceutical ingredients (API) and diagnostic imaging agents. The Company uses its API products in the manufacture of its generic pharmaceuticals and also sells them to other pharmaceutical companies. The Company operates through two segments: Specialty Pharmaceuticals and Global Medical Imaging. The Companys Specialty Pharmaceuticals segment develops manufactures and sells through its Brands business drugs including EXALGO (hydromorphone HCl) Extended-Release Tablets and GABLOFEN. The Companys Global Medical Imaging segment develops manufactures and markets contrast media and delivery systems (CMDS). The Company offers INOMAX Total Care (inhaled nitric oxide) a neonatal critical care product.